InvestorsHub Logo
Followers 41
Posts 1440
Boards Moderated 0
Alias Born 04/05/2009

Re: staccani post# 2855

Wednesday, 02/15/2017 8:53:09 AM

Wednesday, February 15, 2017 8:53:09 AM

Post# of 3834
Look the CX is fine. They will use biopsy. The frustrating part is Traber not getting any dose escalation in THREE years! The reason for the confidence is based on the number of people in the trial and the length of trial. ICPT was able to move the needle on fibrosis after 18 months. this trial is 12 months but a clearly superior if not the BEST MOA. CNAT treats a symptom but not underlying cause. so you get rid of fat you get rid of the mechanical cause forcing your liver to scar. GALT MOA - is I don't care how fat your liver is but your body isn't going to produce collagen to create fibroids.

Got off topic the main thing is that CX is on track there are going to be a lot of statistics that allow them to show something. It will be much better than the standard of care but if they were at 12 mg/kg or higher this is a slam dunk. See we saw with atopic dermatitis and psoriasis that a higher dose was needed but it showed movement and I think we will get enough movement and get enough people below the 10mm of pressure to meet endpoint
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GALT News